Deeplife
AI-driven cell digital twins and multi-omics analysis for pharmaceutical drug discovery and development
Highlights
- New on EvolcAdded 2026-10-30
About Deeplife
DeepLife develops a platform that combines multi-omics data, causal AI and systems engineering to model cellular biology and identify disease mechanisms and drug targets. Its products include TwinCell, an API and a cell blueprint platform.
The company works with partners in drug discovery and development, including on target discovery and drug repositioning. Jonathan Baptista and Jean-Baptiste Morlot founded DeepLife in 2019. Its headquarters are in Vernon, France.
Product: A platform using multi-omics data and causal AI to simulate cellular biology and support target discovery, drug repositioning and drug development.
Jobs at Deeplife
Leadership
- Jonathan Baptista · CEOSource: company website
- Jean-Baptiste Morlot · CTOSource: company website
More biotech & pharma companies
Depixus
Magnetic force spectroscopy instruments for researchers studying biomolecular interactions and drug discoveryNew on EvolcDiogenx
Preclinical biotech developing regenerative protein therapies for type 1 diabetes, aimed at restoring insulin-producing beta cellsNew on EvolcDiscngine
Scientific software and custom IT services for life science research and early drug discovery teamsNew on EvolcDNA Script
Benchtop enzymatic DNA synthesis system for labs that need ready-to-use oligos in-house, overnightNew on EvolcRemote-friendlyDomes Pharma
Veterinary pharmaceutical group making animal health products for vets, pharmacies and pet owners in France and abroadNew on EvolcEdelris
Drug discovery CRO offering compound libraries, screening and medicinal chemistry to pharma and biotech teamsNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- AWS
- Cloudflare
- Google Analytics 4
- Google Tag Manager
- Hotjar
- Webflow